m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG04256)
Name
Radiosensitizer gene therapy
Synonyms
Radiosensitizer gene therapy (prostate cancer)
    Click to Show/Hide
Status
Phase 3
TTD Drug ID
D0X4NF
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Thymidine kinase 1 (TK1)
Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Thymidine kinase 1 (TK1) is a therapeutic target for Radiosensitizer gene therapy. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Radiosensitizer gene therapy through regulating the expression of Thymidine kinase 1 (TK1). [1], [2]
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Thymidine kinase 1 (TK1) is a therapeutic target for Radiosensitizer gene therapy. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Radiosensitizer gene therapy through regulating the expression of Thymidine kinase 1 (TK1). [1], [2]
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Thymidine kinase 1 (TK1) is a therapeutic target for Radiosensitizer gene therapy. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Radiosensitizer gene therapy through regulating the expression of Thymidine kinase 1 (TK1). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Thymidine kinase 1 (TK1) is a therapeutic target for Radiosensitizer gene therapy. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Radiosensitizer gene therapy through regulating the expression of Thymidine kinase 1 (TK1). [1], [2]
References
Ref 1 Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018 Mar;20(3):285-295. doi: 10.1038/s41556-018-0045-z. Epub 2018 Feb 23.
Ref 2 Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase. Mol Pharmacol. 2002 Feb;61(2):249-54. doi: 10.1124/mol.61.2.249.